Esophageal Cancer Market Size, Type, Application and Forecast To 2030
Esophageal Cancer Market Overview
Rated the sixth most common type of cancer affecting patients, esophageal cancer is responsible for numerus deaths worldwide. Tobacco and alcohol consumption, or certain dietary habits can lead to probabilities of attaining the disease. With advances in treatment, diagnostics, and surgical techniques, the prognosis rate of esophageal cancer has improved considerably over the ears. In addition, increase in survival rates, detection at an early stage, and transformation in the field of drug development have all worked in favor of the global esophageal cancer market.
Cancer is one of the leading causes of death worldwide and
is expected to witness the expansion of patient population in the years to
come. One of the types of cancer that affect the food pipe connecting the mouth
and stomach is the esophageal cancer which is majorly prevalent among the older
adults belonging to 55 years and above age group. Market Research Future (MRFR)
has found out that Esophageal Cancer Market is
projected to reach USD 22 billion at CAGR of 8.22% by 2030.
Historically, esophageal cancer had limited treatment options. However,
recent treatment advances are aiding patients to opt for treatment options that
can possibly help them live longer with less side effects. Intensive R&D
activities and clinical trials are being carried out at an accelerated pace.
Combination of various therapies such as chemotherapy with immunotherapy have
demonstrated significant improvement in response rates. Of late, the FDA has
also been approving more immunotherapy drugs for a variety of oncological
disorders, which is likely to uplift the development of the esophageal cancer
market.
Market Segmentation
By type, the global esophageal cancer market has been
segmented into esophageal squamous-cell carcinoma, esophageal adenocarcinoma,
and others.
On the basis of phase, the esophageal cancer market has been
segmented into phase I, phases II, and phases III.
The esophageal cancer market by treatment, has been
segmented into surgery, chemotherapy and radiotherapy and other.
Regional Analysis
Region-wise, the esophageal cancer market has been segmented
into North America, the Middle East & Africa (MEA), Asia Pacific (APAC),
and Europe.
With numerous cases of esophageal cancer, North America has
commanded the leading position in the global market. The population of the
region is highly addicted to tobacco, which remains among the prime causes of
esophageal cancer. High government support, high healthcare expenditure, and
favorable reimbursement landscape is providing impetus to the growth of the
North America market. The US has major contribution to make in the North
America market. Robust healthcare infrastructure and the presence of a wide
population base supports the growth of the market.
Intensive R&D activities in Europe is driving the growth of
the market in Europe. The expansion of the APAC market can be attributed to the
surging incidence rate of esophageal cancer and large unmet needs in the
region.
Competitive Landscape
Esophageal Cancer Market Players includeAmgen
Inc. (U.S.), Boehringer Ingelheim GmbH (Germany), Johnson & Johnson (U.S.),
Eli Lilly and Company (U.S.), Merck & Co., Inc. (U.S.), F. Hoffmann-La
Roche (Switzerland), Novartis AG (Switzerland), GlaxoSmithKline Plc. (U.K), Bristol-Myers
Squibb (U.S.), Bristol-Myers Squibb Company (U.S.), and Gilead Sciences, Inc.
(U.S.) are the eminent players in the global esophageal cancer market.
Industry Updates
August 2019 - A new immunotherapy drug has been approved by the
U.S. Food and Drug Administration (FDA) aimed at treating esophageal cancer.
Dubbed as “Keytruda", the new immunotherapy drug pembrolizumab has
exhibited its efficiency in reducing the risk of fatality in esophageal cancer
patients by 31% in clinical trials. The treatment would be beneficial for those
patients who are unresponsive to chemotherapy. Keytruda is the result of
aggressive R&D by the leading pharmaceutical company, Merck & Co.
At
Market Research Future (MRFR), we enable our customers to unravel the
complexity of various industries through our Cooked Research Report (CRR),
Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have
supreme objective to provide the optimum quality market research and
intelligence services to our clients.
Contact us:
Market
Research Future (part of Wantstats Research and Media Private Limited),
99
Hudson Street, 5Th Floor,
New
York, New York 10013
United
States of America
+1
628 258 0071
Email:
sales@marketresearchfuture.com
.jpg)
Comments
Post a Comment